GlassScriptPhysician profile
Kristina Eberly
NPI 1295900520
$361.77
in general payments reported to CMS, 2019-2025
10 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $22.53 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $66.96 | 2025 | Auvelity |
| Exeltis, USA INC. | $54.53 | 2025 | Slynd |
| Pacira Pharmaceuticals Incorporated | $43.56 | 2024-2025 | Exparel |
| Mayne Pharma Commercial LLC | $41.43 | 2025 | |
| Sage Therapeutics, LLC | $40.38 | 2025 | Zurzuvae |
| Vertex Pharmaceuticals Incorporated | $39.47 | 2025 | |
| Astellas Pharma US INC | $23.23 | 2025 | Veozah |
| Optumhealth Care Solutions, LLC | $19.04 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Bayer Healthcare Pharmaceuticals INC. | $16.98 | 2025 | |
| Supernus Pharmaceuticals, INC. | $16.19 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristina Eberly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.